Read by QxMD icon Read

Mullerian cancer

Christine Decanter, Marc Cloquet, Audrey Dassonneville, Emmanuelle D'Orazio, Audrey Mailliez, Pascal Pigny
The relationship between early recovery of menstrual activity and blood anti-Müllerian hormone (AMH) concentrations were investigated within the first year post-chemotherapy in 32 young patients with breast cancer. All were treated by surgery and the same chemotherapy protocol (three cycles of FEC100 plus three cycles of taxanes). Menstrual activity, blood AMH (using picoAMH ELISA) and FSH concentrations were measured longitudinally before, during and up to 12 months after the end of chemotherapy (six samples per patient)...
March 2, 2018: Reproductive Biomedicine Online
David Kudlowitz, Alejandro Velastegui, Fernanda Musa, Franco Muggia
PURPOSE: We report here on the tolerance of a carboplatin-'divided dose' paclitaxel (given on days 1 and 11) regimen in chemotherapy-naïve patients with resected and staged endometrial epithelial neoplasms deemed at high-risk of recurrence or early stage epithelial high-grade serous tubo-ovarian adenocarcinomas after risk-reducing surgery. More recently, we applied this regimen as neoadjuvant chemotherapy for advanced ovarian cancer presentations. METHODS: A retrospective chart review of patients receiving this day 1, 11 paclitaxel regimens in combination with carboplatin at AUC 6 every 3 weeks since 2004 was carried out by the second author with subsequent updates by the first and third authors...
March 7, 2018: Cancer Chemotherapy and Pharmacology
Christine Decanter, Geoffroy Robin, Audrey Mailliez, Julien Sigala, Franck Morschhauser, Nassima Ramdane, Patrick Devos, Didier Dewailly, Brigitte Leroy-Martin, Laura Keller
A lower number of metaphase II oocytes eligible for vitrification after controlled stimulation in cancer patients has recently been reported, suggesting that cancer may impair the dynamics and quality of follicular growth. In this prospective, non-interventional study, the pattern of follicular growth and oocyte cohort after ovarian stimulation in cancer patients was analysed. Ninety cancer patients, recruited before starting chemotherapy, were compared with 180 time- and age-matched healthy controls undergoing intracytoplasmic sperm injection...
February 19, 2018: Reproductive Biomedicine Online
Michael J Bertoldo, Kirsty A Walters, William L Ledger, Robert B Gilchrist, Pascal Mermillod, Yann Locatelli
Ovarian tissue is increasingly being collected from cancer patients and cryopreserved for fertility preservation. While the only available option to restore fertility is autologous transplantation, this treatment is not appropriate for all patients due to the risk of reintroducing cancer cells and causing disease recurrence. Harnessing the full reproductive potential of this tissue to restore fertility requires the development of culture systems that support oocyte development from the primordial follicle stage...
February 13, 2018: Reproductive Biomedicine Online
Iris Yaish, Foad Azem, Orit Gutfeld, Zmira Silman, Merav Serebro, Orli Sharon, Gabi Shefer, Rona Limor, Naftali Stern, Karen M Tordjman
BACKGROUND: Women of reproductive age with differentiated thyroid cancer (DTC) often need to receive radioactive iodine (RAI) treatment after surgery. In contrast to the well documented effect of RAI on testicular function, the potential negative effects of this treatment on ovarian reserve have been largely dismissed. The objective of this pilot study was to examine the possibility that RAI treatment is deleterious to the ovarian reserve by prospectively measuring the concentration of anti-Müllerian hormone (AMH) after this treatment...
February 21, 2018: Thyroid: Official Journal of the American Thyroid Association
V G Vellone, B Spina, F Grillo, P Calamaro, F Sarocchi, P Sala, S Ferrero, E Fulcheri
Chemo-radiation represents an effective therapy for carcinoma of the uterine cervix. The endometrium may however receive a consistent dose of mutagenic radiations and patients may have an increased risk of secondary malignancies. Endometrial mixed malignant mullerian tumor (MMMT) is a rare, highly aggressive disease, and neuroendocrine features are even rarer. A 68 years old woman underwent radio-chemotherapy for a squamous cell carcinoma of the cervix. Follow up was uneventful until, eight years after radio-chemotherapy, imaging exams detected a diffuse enlargement of the uterine body...
December 2017: Pathologica
Michael Grynberg
Michaël Grynberg is an Obstetrician Gynecologist specialized in reproductive medicine. After 1 year as a visiting fellow in the Department of Reproductive Medicine at Cornell University, he returned to work in France as an Attending Physician in the Division of Reproductive Medicine at the University Hôpital Antoine Béclère, Clamart, France. In 2011, he completed his PhD on the topic of the regulation of follicular growth and anti-Müllerian hormone production. Since 2014, he has been Professor of Reproductive Medicine and the Head of the Department of Reproductive Medicine and Fertility Preservation at the University Hospital Jean Verdier, Bondy, France...
February 9, 2018: Future Oncology
Jiaheng Li, Riqiang Bao, Shiwei Peng, Chunping Zhang
Over these years, more and more sex cord-stromal tumors have been reported. Granulosa cell tumor (GCT) is a rare tumor in ovaries, accounts for 2% to 5% of ovarian cancers. The main different feature of GCTs from other ovarian cancers is that GCTs can lead to abnormally secreted hormones (estrogen, inhibin and Müllerian inhibiting substance). The GCT is divided into two categories according to the age of patients, namely AGCT (adult granulosa cell tumor) and JGCT (Juvenile granulosa cell tumor). AGCT patients accounts for 95%...
February 6, 2018: Journal of Ovarian Research
Katherine E Cameron, Martha B Kole, Mary D Sammel, Jill P Ginsberg, Yasmin Gosiengfiao, Jennifer E Mersereau, H Irene Su, Clarisa R Gracia
PURPOSE: The aim of this study was to evaluate the prevalence of menopausal symptoms in young cancer survivors immediately following the completion of chemotherapy. METHODS: This prospective cohort study followed 124 young females with a new diagnosis of cancer requiring chemotherapy to assess symptoms of menopause before treatment and immediately following chemotherapy. Symptoms were compared before and after treatment using the McNemar test and between cancer patients and 133 similar-aged healthy controls using Pearson χ2 and Fisher's exact tests...
January 26, 2018: Oncology
Angela Russo, Austin A Czarnecki, Matthew Dean, Dimple A Modi, Daniel D Lantvit, Laura Hardy, Seth Baligod, David A Davis, Jian-Jun Wei, Joanna E Burdette
The signaling events involved in the onset of ovarian cancer from the fallopian tube epithelium (FTE) are crucial for early detection and treatment of the disease, but they remain poorly defined. Conditional homozygous knockout of PTEN mediated by PAX8-cre recombinase was sufficient to drive endometrioid and serous borderline ovarian carcinoma, providing the first model of FTE-derived borderline tumors. In addition, heterozygous PTEN deletion in the FTE resulted in hyperplasia, providing a model to study early events of human ovarian pathogenesis...
January 25, 2018: Oncogene
Kimberly A Bertrand, A Heather Eliassen, Susan E Hankinson, Bernard A Rosner, Rulla M Tamimi
Prior research suggests that several endogenous hormones in premenopausal women are associated with breast cancer risk; however, few studies have evaluated associations of endogenous hormones with mammographic density (MD) in premenopausal women. We conducted a cross-sectional study of plasma hormone levels in relation to MD among 634 cancer-free premenopausal women in the Nurses' Health Study II. We measured percent MD from screening mammograms using a computer-assisted method. We assayed estradiol, estrone, and estrone sulfate in blood samples timed in early follicular and mid-luteal phases of the menstrual cycle as well as testosterone, androstenedione, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate, sex hormone-binding globulin (SHBG), and anti-Müllerian hormone in luteal or untimed samples...
January 12, 2018: Hormones & Cancer
Wenzhen Ge, Tess V Clendenen, Yelena Afanasyeva, Karen L Koenig, Claudia Agnoli, Louise A Brinton, Joanne F Dorgan, A Heather Eliassen, Roni T Falk, Göran Hallmans, Susan E Hankinson, Judith Hoffman-Bolton, Timothy J Key, Vittorio Krogh, Hazel B Nichols, Dale P Sandler, Minouk J Schoemaker, Patrick M Sluss, Malin Sund, Anthony J Swerdlow, Kala Visvanathan, Mengling Liu, Anne Zeleniuch-Jacquotte
A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case-control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation...
January 8, 2018: International Journal of Cancer. Journal International du Cancer
Massimo Giusti, Miranda Mittica, Paola Comite, Claudia Campana, Stefano Gay, Michele Mussap
PURPOSE: In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer. METHODS: Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancer women (41.6 ± 7...
January 4, 2018: Endocrine
Vadsala Baskaran, Laura Pugh, Robert James Berg, John Anderson
Endobronchial metastasis occurs in only 2%-5% of non-pulmonary cancers. Here we report on an 84-year-old woman who presented with breathlessness and light-headedness while on holiday in Australia, 2 years post-treatment for endometrial cancer. Initial CT pulmonary angiogram identified a soft tissue mass in the left hemithorax. A chest radiograph performed after repatriation was consistent with a large left pleural effusion, but bedside ultrasound showed a lobulated mass involving the left hemidiaphragm. A pleural procedure in the traditional 'triangle of safety' would have resulted in inadvertent puncture of the underlying mass...
December 28, 2017: BMJ Case Reports
P A Peres Fagundes, R Chapon, P R Olsen, A K Schuster, M M C Mattia, J S Cunha-Filho
BACKGROUND: Several studies have reported a correlation between antral follicle count by conventional 2D transvaginal sonography and serum anti-Müllerian hormone levels. However, few studies have investigated the effectiveness of 3D SonoAVC transvaginal ultrasound technology, particularly in infertile women. Therefore, this study aims to evaluate the usefulness of three-dimensional (3D) SonoAVC transvaginal ultrasound technology for antral follicle count and its correlation to conventional two-dimensional (2D) transvaginal ultrasound and serum levels of anti-Müllerian hormone in infertile women...
December 16, 2017: Reproductive Biology and Endocrinology: RB&E
Houcine Bougherara, Fariba Némati, André Nicolas, Gérald Massonnet, Martine Pugnière, Charlotte Ngô, Marie-Aude Le Frère-Belda, Alexandra Leary, Jérôme Alexandre, Didier Meseure, Jean-Marc Barret, Isabelle Navarro-Teulon, André Pèlegrin, Sergio Roman-Roman, Jean-François Prost, Emmanuel Donnadieu, Didier Decaudin
Müllerian inhibiting substance, also called anti-Müllerian hormone (AMH), inhibits proliferation and induces apoptosis of AMH type II receptor-positive tumor cells, such as human ovarian cancers (OCs). On this basis, a humanized glyco-engineered monoclonal antibody (3C23K) has been developed. The aim of this study was therefore to experimentally confirm the therapeutic potential of 3C23K in human OCs. We first determined by immunofluorescence, immunohistochemistry and cytofluorometry analyses the expression of AMHRII in patient's tumors and found that a majority (60 to 80% depending on the detection technique) of OCs were positive for this marker...
November 21, 2017: Oncotarget
William T Jaegle, Jason C Barnett, Bridget R Stralka, Nicole P Chappell
Background: Tamoxifen is a medication often used for the treatment and prevention of breast cancer. It is classically associated with several gynecological side effects to include a thickened endometrial stripe, increased uterine polyp formation, and an increased risk of uterine cancer. Rarely tamoxifen use has been associated with proliferation of endometriosis often severe enough to mimic a late-stage gynecologic malignancy. Case: A 62-year-old Gravida 0 postmenopausal female with a medical history of severe obesity, infertility, and preventative tamoxifen use presented for evaluation of gross hematuria...
November 2017: Gynecologic Oncology Reports
Angela Pang, Mariana Carbini, Andre L Moreira, Robert G Maki
In this review, we outline the biology and management of patients with carcinosarcomas and related malignancies, which are often included under the broader concept of sarcomatoid carcinomas. Carcinosarcomas are unusual tumors that are commonly gynecologic in origin, where they are referred to as malignant mixed Müllerian tumors, but may appear in any anatomic site. Although a variety of hypotheses have been presented as to the biphasic nature of these tumors, carcinosarcomas seem to represent the best example in human cancers of the concept of epithelial-mesenchymal transition (EMT), in which the two parts of the tumor are genomically related to one another, as opposed to the mesenchymal component that represents a second neoplasm or (benign) reactive process...
January 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
M M Smit, K J Ekenstedt, K M Minor, C K Lim, Paj Leegwater, E Furrow
Persistent Müllerian duct syndrome (PMDS) is a sex-limited disorder in which males develop portions of the female reproductive tract. Important consequences of PMDS are cryptorchidism and its sequelae of infertility and increased risk of testicular cancer. Anti-Müllerian hormone (AMH) and its receptor (AMHR2) induce the regression of the Müllerian ducts in male embryos. In Miniature Schnauzer dogs, the genetic basis has been identified as an autosomal recessive nonsense mutation in AMHR2, but the allele frequency of the mutation is unknown...
December 1, 2017: Reproduction in Domestic Animals, Zuchthygiene
Hong-Wei Tian, Wei-Bing Yang, Meng-Jie Yang, Jing-Yuan Liu, Jian-Chu Zhang, Xiao-Nan Tao, Qiong Zhou
The lungs are one of the most common organs to which cancer metastasizes, but are a location not common for uterine sarcoma. A malignant mixed Müllerian tumor (MMMT) of the uterus is an extremely rare and aggressive sarcoma, characterized by a mixture of epithelial and mesenchymal components. There are few reports regarding the pulmonary metastasis from MMMTs. The present study presents the case of a 58-year-old woman with hemoptysis and post-menopausal vaginal bleeding. The woman was initially diagnosed with invasive aspergillosis based on a chest computed tomography (CT) scan showing multiple pulmonary nodular opacities surrounded by a ground-glass attenuation halo (halo-sign)...
December 2017: Oncology Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"